### Corporate Overview and Strategic Pivot **Medico Intercontinental Limited**, headquartered in **Ahmedabad**, is an Indian pharmaceutical entity that has successfully transitioned from its historical roots in the textile industry to become a specialized player in the healthcare sector. The company leverages a robust distribution network and a management team with deep industry expertise to scale its operations across **60 therapeutic categories**. The company is currently executing a transformation strategy centered on **inorganic growth**, **vertical integration**, and **capital expansion**. By moving beyond its traditional trading model into active manufacturing and specialized joint ventures, Medico is positioning itself to capture high-growth segments within the Indian pharmaceutical market. --- ### Group Structure and Manufacturing Integration The company operates through a consolidated group structure designed to balance wide-scale distribution with specialized manufacturing capabilities. | Entity Name | Relationship | Nature of Business | |:---|:---|:---| | **Evagrace Pharma Private Limited** | Wholly Owned Subsidiary | Pharmaceutical Trading | | **Ritz Formulations Private Limited** | Wholly Owned Subsidiary | Pharmaceutical Trading | | **Sungrace Pharma Private Limited** | Wholly Owned Subsidiary | Pharmaceutical Trading | | **Azillian Healthcare Private Limited** | Wholly Owned Subsidiary (Material) | Pharmaceutical Trading | | **Calborn Lifescience Private Limited** | Subsidiary (**51% Stake**) | **Manufacturing** of drugs, APIs, and intermediates | | **Medico Lab** | Joint Venture (**50% Investment**) | Laboratory and Healthcare Services | **Strategic Vertical Integration:** In **April 2025**, the company achieved a major milestone by acquiring a **51% stake** in **Calborn Lifescience Private Limited**. This move marks a definitive shift from pure trading to the **manufacturing, import, and export** of drugs, surgical equipment, and diagnostic kits. A primary objective of this acquisition is to secure a foothold in the **Vitamin D3** product portfolio. --- ### Market Positioning and Growth Drivers The company’s strategy is closely aligned with the evolving Indian healthcare landscape and government-led initiatives: * **Therapeutic Focus:** Management has identified high-growth opportunities in **Anti-Infectives** (specifically **Amoxy Clav**, **Ceftriaxone**, and **Meropenem**), **Oncology**, and **Vaccines**, all of which are currently outpacing the 5-year industry CAGR. * **Distribution Advantage:** The company utilizes a cumulative distribution network to rapidly scale new product introductions. It is also expanding its reach through the **Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)** network and **e-pharmacy** channels. * **Strategic Alliances:** To achieve broader market penetration for new brands, the company actively employs **co-marketing agreements** and operational partnerships, such as the **Medico Lab** joint venture established in **April 2024**. * **Policy Alignment:** The company is positioning itself to capitalize on the **Production Linked Incentive (PLI)** and **Strengthening of Pharmaceutical Industry (SPI)** schemes to enhance domestic manufacturing. --- ### Financial Performance and Solvency Metrics The company has demonstrated consistent top-line and bottom-line growth, characterized by improved margins and a significantly strengthened balance sheet. **Audited Financial Summary:** | Metric | FY 2022-23 (Rs. in Crore) | FY 2021-22 (Rs. in Crore) | | :--- | :--- | :--- | | **Total Income** | **49.23** | **39.43** | | **Net Profit** | **1.70** | **1.31** | | **Net Profit Margin** | **3.49%** | **3.34%** | | **Operating Profit Margin** | **13.84%** | **13.22%** | **Key Financial Ratios (as of March 31, 2023):** * **Debt Equity Ratio:** Improved significantly to **0.29:1** (from **1.32:1**), indicating a reduced reliance on external debt. * **Current Ratio:** Increased to **4.17:1** (from **2.93:1**), reflecting high short-term liquidity. * **Interest Coverage Ratio:** Rose to **7.47:1** (from **4.51:1**). * **Inventory Turnover:** **13.69:1**, showing efficient stock management. * **Subsidiary Contribution (FY24):** The four wholly owned subsidiaries generated **₹33.47 crore** in revenue and **₹2.2 crore** in PAT. --- ### Capital Structure and Valuation To facilitate its aggressive inorganic growth strategy, the company has expanded its financial headroom: * **Share Capital Expansion:** The **Authorised Share Capital** was doubled from **Rs. 10 Crores** to **Rs. 20 Crores** (divided into **2 Crore equity shares** of **Rs. 10 each**) in mid-2024. * **Preferential Allotment:** During FY 2022-23, the company issued **67,51,000 Equity Shares** on a preferential basis, increasing the total paid-up capital to **Rs. 10.00 Crore** (**1,00,00,000 shares**). * **Borrowing & Investment Limits:** Proposed increases in borrowing powers and investment limits to **Rs. 100 Crores** each allow the company to respond rapidly to acquisition opportunities. * **Equity Valuation:** An April 2025 assessment using the **Comparable Company Method** derived a **Price / Sales Multiple** of **2.89**. After a **20% discount** for lack of marketing, the **Equity Value per Share** was assessed at **Rs. 35**, with a total equity value of **Rs. 660.60 Lakhs**. * **Promoter Holding:** Promoters hold **55.17%** of the equity (as of March 2025), with **99.07%** of total shares held in **dematerialized form**. --- ### Governance and Management The company maintains a structured governance framework with a focus on compliance and professional oversight. * **Board Composition:** **6 Directors**, comprising **1 Executive Director**, **2 Non-Executive Directors**, and **3 Independent Directors**. * **Key Leadership:** * **Managing Director:** Samir D. Shah (Remuneration: **Rs. 60 Lakhs** base salary) * **CEO:** Dilipkumar B. Shah * **CFO:** Jay S. Shah * **Audit Oversight:** Statutory audits are performed by **V. Goswami & Co.**, while secretarial audits for the parent and its material subsidiary (**Azillian Healthcare**) are conducted by **Yash Mehta & Associates**. --- ### Risk Mitigation and Future Outlook The company actively monitors several risk vectors to ensure long-term viability: * **Financial Risk:** * **Liquidity:** Managed through rolling cash flow forecasts and maintaining **committed credit facilities**. * **Credit:** Mitigated by establishing strict credit limits for a **large, diversified customer base**. * **Interest Rate:** Monitoring floating rate debt; however, operating cash flows are currently largely independent of rate changes. * **Operational & Regulatory Risk:** * **Social Security Code, 2020:** Potential future impacts on **Provident Fund and Gratuity** contributions are being monitored. * **Market Competition:** The rise of **e-pharmacies** (growing at **>25%**) and pricing pressures from consolidation are key challenges. * **Defined Benefit Obligations:** As an **unfunded** plan, the company manages **Gratuity** payouts on a **"pay as you go"** basis, sensitive to **G.Sec. Rate** fluctuations and salary inflation. * **Foreign Exchange:** As of **March 31, 2025**, the company reported **no outstanding payables** for imported materials, minimizing immediate currency risk. Management remains optimistic, citing the expansion of the **Ayushman Bharat** scheme (targeting **4 crore** beneficiaries) and the company's new manufacturing capabilities as primary catalysts for future value creation.